Biotech Receives First Approval; Drug Now Available November 29, 2023 (Investorideas.com Newswire) Recently, SpringWorks Therapeutics Inc. announced FDA approval of OGSIVEO (nirogacestat) for treating progressing desmoid tumors (DT) in adult patients based on Phase 3 DeFi trial results

Biotech Stock News - BioHarvest Sciences (CSE: BHSC) Reports Q3 2023 Revenue Demonstrating Continued Growth Momentum Vancouver, British Columbia and Rehovot, Israel - November 29, 2023 (Newsfile Corp.) (Investorideas.com Newswire) BioHarvest Sciences Inc, (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) announces that it has released Q3 2023 results.

Encouraging Early Data For Biotech's Cancer Therapies November 22, 2023 (Investorideas.com Newswire) In a recent corporate update, Purple Biotech Ltd. reported positive interim Phase 1/2 data for NT219 and accelerated enrollment for CM24

Strong Early Launch Metrics for Biotech's Skin Disease Drug November 21, 2023 (Investorideas.com Newswire) Oren Livnat of H.C. Wainwright and Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.

Arizona Biotech Advances Multiple Cell Therapies November 17, 2023 (Investorideas.com Newswire) Roth MKM has a US$30 price target on this biotech company based on progress across its regenerative medicine pipeline

Massachusetts Biotech Advances Novel Cytokine Therapies November 16, 2023 (Investorideas.com Newswire) Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline

Texas Biotech Exceeds Alzheimer's Trial Enrollment Target November 9, 2023 (Investorideas.com Newswire) This Texas-based biotech company's enrollment in its two pivotal Phase 3 trials evaluating lead drug candidate simufilam for Alzheimer's disease surpassed initial enrollment targets

Massachusetts Biotech Presents Catalysts Into 2024 November 9, 2023 (Investorideas.com Newswire) Cambridge, Massachusetts-based iTeos Therapeutics presented multiple upcoming catalysts into 2024 after reporting Q3 results

Biopharma Acquires Royalty on Approved Diabetes Drug November 6, 2023 (Investorideas.com Newswire) This is one of the California-based company's many transactions resulting from its royalty monetization strategy

Survey Results Positive for New HAE Drug November 3, 2023 (Investorideas.com Newswire) Most responding physicians, all with hereditary angioedema patients, indicated an "above average" impression of the treatment's safety and efficacy data

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

The Rise of Mobile Applications in Healthcare and Medicine - September 5, 2023

How to Prove Wrongful Death - February 1, 2022

Healthcare Supply Chain Management Software - November 29, 2021

Overview of Biotech Stocks - What Could Happen by the End of 2021? - November 3, 2021

Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021

Resources for Physicians and Medical Practices - December 31, 2020

Lockdown Part 2: The South African Economy and the Rand - December 15, 2020

How to Get Into Canada during COVID - November 30, 2020

The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020

Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020

Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020

The Rise Of The At-Home Testing Market - January 16, 2020

Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019

5 Key Tips For Renting a Boardroom - August 14, 2018

How to Go About Choosing a Medical Malpractice Lawyer - February 13, 2018

BioHarvest Sciences to Host Virtual Shareholder Update December 13, 2023, 2:30pm ET Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 1, 2023) -  BioHarvest Sciences Inc. ("BioHarvest" or the "Company") (CSE: BHSC) (OTCQB: CNVCF) announces that it is hosting the Q3 Performance Update Presentation on Wednesday, December 13, 2023, at 11:30 am PST | 2:30 pm EST. The interactive session will be hosted by Ilan Sobel, CEO of BioHarvest Sciences."I am currently in Nashville, Tennessee, as part of a U.S. media and operational partner tour ahead of the imminent...

Braxia Scientific Reports Q2 2024 Financial Results and Provides Corporate Update Toronto, Ontario--(Newsfile Corp. - November 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended September 30, 2023. Complete financial statements along with...

Britannia Life Sciences Inc. Announces Second Quarter Results Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) ("Britannia" or the "Company") is pleased to provide its unaudited financial results for the three- and six- month periods ended September 30, 2023. These filings and additional information regarding Britannia are available for review on SEDAR at www.sedar.com. All amounts are Canadian dollars unless otherwise stated."We are pleased that the first six months of Fiscal 2023 saw revenue...

PurMinds Chief Innovation Officer to Speak at the Analytical Cannabis Educational Webinar about Next Generation Psychedelics and the Neurobiology of Neuroplastogens Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - November 29, 2023) -  PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on neurological and neurodegenerative disorders and advancing a robust clinical development pipeline of small molecules, psychedelic compounds and other modalities, today announced that Dr. Amy Reichelt, Ph.D., the company's Chief Innovation Officer, will be speaking at the Analytical Cannabis Educational Webinar...

Therma Bright Prepares FDA 513(g) Review Document for its AI-Driven Digital Cough Analyzer (DCA) Toronto, Ontario--(Newsfile Corp. - November 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, with its development partner AI4LYF, an artificial intelligence (AI) driven technology firm that operates an ISO/IEC 27001 and ISO: 9001 certified facility, announced today that its AI-driven Digital Cough Analyzer (DCA) is ready for a 513(g)...

Subscribe to Biotech News